<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167775</url>
  </required_header>
  <id_info>
    <org_study_id>81YY-ZLLL-16-19</org_study_id>
    <nct_id>NCT03167775</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer</brief_title>
  <official_title>Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiJing Yijiayi Medicine Techonoloy Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dalian Holley Kingkong Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiJing Yijiayi Medicine Techonoloy Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best
      Supportive Treatment in the Treatment of Advanced Primary Liver Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced primary liver cancer will be enrolled in the trial , then the patients
      will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the
      best supportive treatment .The purpose of the study is to evaluate the effect and safety of
      the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive
      treatment in the treatment of advanced primary liver cancer
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Anticipated">November 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 27, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DCR and/or 6-months survival rate</measure>
    <time_frame>6 months</time_frame>
    <description>Disease control rate.The proportion of patients who had a best response rating of complete response, partial response, or stable disease/</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>1year</time_frame>
    <description>Objective response rate.The proportion of patients who had a best response rating of complete response and partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Progression-free survival.The time of patients from randomization to death caused by the progression of the tumor or any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>3 year</time_frame>
    <description>Overrall survival.The time of patient from randomization to death caused by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLQ</measure>
    <time_frame>3 year</time_frame>
    <description>Quality of Life Questionnaire Core 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of incidence of adverse events</measure>
    <time_frame>3 year</time_frame>
    <description>NCI CTC AE 4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Elemene + the best supportive treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the patients will be treated with the Elemene Injection/Elemene Oral Emulusion in Combination with the best supportive treatment .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elemene Injection/Elemene Oral Emulusion</intervention_name>
    <arm_group_label>Elemene + the best supportive treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years old，No limit on gender

          -  Patients who are confirmed Locally advanced or metastatic primary liver cancerin
             accordance with the clinical diagnostic criteria , or by pathological histology or
             cytology examination, Patients who are unable to accept surgery,radiofrequency
             ablation、TACE and local therapy ，orLocal treatment progress failed

          -  have systematic treatment before( including systematic chemotherapy and/or molecular
             targeted therapy) , but the treatment was unsuccessed and the tumor progress

          -  According to RECIST V1.1，1at least has one measurable lesions

          -  ECOG Score ≤2

          -  Patients who have primary liver cancer with Child - Pugh liver function grade rating A
             or better B(score&lt;=7)

          -  Laboratory inspection basically meets the following requirements： Blood test：a.
             Hb&gt;=90g/L(without blood transfusion within 14 days), b. ANC&gt;=1.5×10^9/L, c.
             PLT&gt;=60×10^9/L. Biochemical test：a. ALB&gt;=29g/L(without blood transfusion within 14
             days), b. ALT and AST &lt;=5ULN, c. TBIL&lt;=2ULN, d. Cr&lt;=1.5ULN. Blood Coagulation
             function:PT&lt;=ULN+6seconds.

          -  Life expectancy of at least 3 months

          -  Subjects join the study voluntarily, sign a consent form, have good compliance, and
             comply with follow-up.

        Exclusion Criteria:

          -  Patients have other anti-cancer treatment ， including α-IFN，Arsenious Acid Injection
             and other Traditional Chinese Medicine Patent Prescription for treating cancer

          -  In the past or at the same time,patients were diagnosed with other malignant tumor
             which have not been cured. As for skin basal cell carcinoma and cervical carcinoma in
             situ,they can be excepted

          -  Patients with severe acute infection and cann't be controled , Chronic suppurative
             infection , body temperature&gt;=39℃ ， Pleural effusion（medium and large） combined with
             infection

          -  Women who is pregnant or during breast feeding and not willing to contraception during
             the test

          -  Coagulation dysfunction(PT&gt;16 seconds ， APTT&gt;43 seconds , TT&gt;21 seconds , Fib&lt;2g/L) ,
             With bleeding tendency or the presence of vital organ thrombosis (lung, brain) is
             receiving thrombolytic or anticoagulant therapy

          -  With a mental illness, or has a history of drugs abuse

          -  Patients accepted any experimental drugs in the past 4 weeks

          -  Other reasons the researchers think not suitable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shukui Qin</last_name>
    <phone>025-80864541</phone>
    <email>qinsk@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Medical University Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaimin Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

